This article is more than 5 years old. Information may no longer be current.
Cologuard surpasses colorectal cancer screening milestone
Click Here to Manage Email Alerts
More than 2 million Americans have been screened for colorectal cancer with Cologuard since the stool-based DNA test received FDA approval in 2014, according to a company press release.
“Cologuard is changing how Americans get screened for colorectal cancer and, importantly, helping many people do so for the first time,” Kevin Conroy, chairman and CEO of Exact Sciences, said in the release. “Reaching this milestone, just a year after the first million patients screened with Cologuard, means more patients and health care providers are empowered by early detection when colorectal cancer is more treatable.”
Exact Sciences, the stool test’s manufacturer, estimates the test may have helped detect as many as 9,400 early-stage cancers and approximately 64,000 pre-cancerous polyps, according to the release.
Additionally, according to the release, nearly half of individuals screened using Cologuard had previously never been screened for colorectal cancer.